Interleukin-6 polymorphisms and the risk of cervical cancer

Int J Gynecol Cancer. 2006 May-Jun;16(3):1278-82. doi: 10.1111/j.1525-1438.2006.00521.x.

Abstract

Recent data implicate that cytokine gene polymorphisms are important in pathogenesis of various neoplastic and nonneoplastic human diseases, and it was recently suggested that polymorphisms in interleukin (IL)-6 might increase the risk of gynecological malignancies, including cervical carcinomas. The aim of this case-control study is to compare the IL-6 polymorphisms in cervical cancer patients and healthy controls and to assess whether any of these polymorphisms would increase the risk of developing cervical cancer. The material in this case-control study consists of 56 patients with cervical carcinoma and 253 population-based control subjects, all ethnic Brazilian women. Control subjects were cancer-free women, following a negative cervical cytology and colposcopy. IL-6 genotyping was performed using a polymerase chain reaction-based restriction fragment length polymorphism. Distribution of the GG, GC, and CC genotypes in cases and controls was significantly different (P= 0.033). Compared with the GG genotype as reference, the adjusted odds ratio for the combined GC and CC genotypes in cancer patients was 1.90 (95% confidence interval, 1.1-3.4). These data suggest that women carrying at least one C genotype in their IL-6 promoter region (-174G-->C) are at higher risk of developing cervical cancer.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Carcinoma / epidemiology
  • Carcinoma / genetics*
  • Case-Control Studies
  • Female
  • Genetic Predisposition to Disease* / epidemiology
  • Genotype
  • Humans
  • Interleukin-6 / genetics*
  • Middle Aged
  • Polymorphism, Genetic*
  • Polymorphism, Restriction Fragment Length
  • Risk Factors
  • Uterine Cervical Neoplasms / epidemiology
  • Uterine Cervical Neoplasms / genetics*

Substances

  • Interleukin-6